LYFECYCLE
29.8.2021 11:50:06 CEST | Business Wire | Press release
Lyfecycle has teamed up with plant-based burger chain Neat Burger and Extreme E, the electric offroad racing series, on a mission to build greater awareness about plastic pollution and the need for action, through the creation of a ‘Reach for Change’ limited edition bracelet.
Lyfecycle, created by British innovators Polymateria, aims to tackle the global plastic pandemic. Lyfecycle’s unique technology allows every chance for recycling to happen and offers a “Plan B” for the 32 per cent of plastic that escapes the circular economy and winds up in the natural environment. Through time-set biodegradation, Lyfecycle products return to nature in a little over a year, leaving no toxins or microplastics behind, compared to the thousands of years it is estimated that typical plastics take to break down.
It is estimated that the Arctic Ocean ice contains 12,000 particles of microplastic per litre – higher than in any other ocean in the world. Scientists predict that over time these small particles trap heat within sea ice, which accelerates melting associated with global climate change.
Inspired by nature and powered by science, the ‘Reach for Change’ bracelet features one-of-a-kind sustainable beads repurposed from Lyfecycle cups used at Extreme E’s Arctic X Prix, an adjustable cord from recovered plastic bottles, and a recycled fair trade silver emblem. It is a tangible example of how Lyfecycle materials designed for biodegradation can also be upcycled into high value items such as jewellery thanks to the unique time-set biodegradation property. Redefining the way we think about and design plastics is essential if we are to solve the plastic pandemic.
All bracelets also come with some educational facts about plastic pollution and the steps we can all adopt to help us to lower our daily usage, and recycle more. It serves as a daily reminder that small actions when multiplied by millions contribute to a big change.
The campaign is set to launch during the 2021 Extreme E race in Kangerlussuaq, where attendees will be asked to get involved and help spread the message.
The competition will also be extended to Game Changers across the world, who are taking small steps toward making a positive impact on the environment. Consumers are encouraged to enter for a chance to win at www.lyfecycle.com/reachforchange . 50 winners will be announced on September 15, 2021. Each winner will receive two bracelets, one for themselves and one to gift to another Game Changer.
Niall Dunne, CEO of Polymateria said: “Our collaboration with fellow disruptors Neat Burger and Extreme E is to provide industry with an example of how recycling and biodegradation can work together and put consumers at the heart of the type of change we need to see to address plastic pollution at scale.”
Alejandro Agag, Founder and CEO of Extreme E said: “Extreme E is a platform to accelerate change. We bring disruptive innovators together and push boundaries not only in motorsport but across all industries. It is the adoption of new technologies that we want to promote because they have the power to improve our world.
“Lyfecycle is a great example of a solution to plastic pollution that works and can be scaled immediately whereas the limited-edition bracelet is a reminder that everyone has a role to play and action has to come from every corner.”
Stasi Nychas, Co-Founder and COO at Neat Burger said: “We are delighted to team up with Lyfecycle on a campaign that echoes our values. As the world’s first plant-based sustainable burger chain, we are committed to championing environmental sustainability and playing our part in positively impacting the environment. Therefore, we are proud to have partnered with Lyfecycle, whose team is dedicated to spreading awareness and promoting solutions to plastic pollution.”
NOTES TO EDITORS
About Lyfecycle:
Lyfecycle is a new solution from British Innovators Polymateria to tackle the global plastic pandemic. The unique Lyfecycle technology allows every chance for recycling to happen and offers a “Plan B” for the 32% of plastic that escapes the circular economy and winds up in the natural environment. Through time-set biodegradation, Lyfecycle products return to nature in a little over a year leaving no toxins and microplastics behind.
Lyfecycle packaging solutions give individuals a more easily achievable way to take small actions toward responsible disposal that will have an immediate and global positive impact on the environment. Through collaborative partnerships, awareness building, and scientific innovation, Lyfecycle’s goal is to ignite action and cause a ripple effect that will solve ocean pollution, and leave the planet in a better place for generations to come.
About Extreme E:
Extreme E is a radical new racing series, which will see electric SUVs competing in extreme environments around the world which have already been damaged or affected by climate and environmental issues. The five-race global voyage highlights the impact of climate change and human interference in some of the world’s most remote locations and promotes the adoption of electric vehicles in the quest for a lower carbon future for the planet.
About Neat Burger:
Founded in collaboration with F1 legend Lewis Hamilton, the group is loved by plant-based and meat eaters alike, serving up a fresh approach to vegan dining while satisfying everyone’s craving for American style food that tastes just like the real thing. Neat Burger works in association with The Eden Projects where for every product sold, a tree is planted.
About Anchor & Crew:
Combining British craft manufacturing with a discerning modern-minimalist style, ANCHOR & CREW is a jewellery and accessories brand that is both multi-award winning ever since 2014 and believers in having a highly ethical and traceable supply chain. ANCHOR & CREW is driven to empower consumers to make the right choice with radical transparency and enact change within their industry.
Honorable Mentions:
Carbon-neutral cup supplier Cupstorys, Imperial College London, Protolabs, and Lyfecycle’s own innovation labs that made this unique piece of jewellery possible.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210829005016/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
